Research Projects to Enhance Applicability of Mammalian Models for Translational Research (R01 Clinical Trial Not Allowed)
ID: 349912Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/349912

Additional Information

http://grants.nih.gov/grants/guide/pa-files/PAR-23-281.html
Timeline
    Description

    The National Institutes of Health (NIH) is offering a funding opportunity titled "Research Projects to Enhance Applicability of Mammalian Models for Translational Research," aimed at improving the utility of mammalian cancer and tumor models in translational research. This initiative encourages applicants to address translational deficiencies in existing mammalian models and propose innovative applications that enhance their relevance to human biology and clinical outcomes. The funding is available for a maximum project period of five years, with an annual budget limit of $499,000, and is open to a wide range of eligible applicants, including various educational institutions, nonprofits, and foreign entities. Interested parties should submit their applications by September 7, 2026, and can direct inquiries to NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at http://grants.nih.gov/grants/guide/pa-files/PAR-23-281.html for further details.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    PAR-23-281.html
    The National Cancer Institute (NCI) under the Department of Health and Human Services is issuing a Notice of Funding Opportunity (NOFO) titled “Research Projects to Enhance Applicability of Mammalian Models for Translational Research”. This initiative, under the R01 grant mechanism, aims to solicit applications focused on improving the use of mammalian cancer and tumor models in translational research, emphasizing their relevance to human biology and clinical applications. Applicants are encouraged to address translational deficiencies in existing mammalian models and propose innovative uses of these models in cancer research. Key dates for application submissions start from September 5, 2023, with deadlines through June 2026 and the maximum project period set at five years with a budget limit of $499,000 annually. Eligible entities include various higher education institutions, nonprofits, for-profits, and government agencies, including foreign institutions. This NOFO aims to foster collaboration within the Oncology Models Forum, leading to advancements in cancer research practices. The document includes details on application procedures, criteria for review, and compliance with federal regulations, highlighting the increasing necessity for practical solutions in the translational use of cancer models.
    Similar Opportunities
    Research Projects to Enhance Applicability of Mammalian Models for Translational Research (R01 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Research Projects to Enhance Applicability of Mammalian Models for Translational Research (R01 Clinical Trial Not Allowed)," aimed at improving the utility of mammalian cancer models in translational research. This initiative seeks projects that enhance the accuracy and application of models, such as organoids and tumoroids, to better represent human biology and inform clinical practices, addressing current limitations and fostering innovation in cancer research methodologies. Eligible applicants include a diverse range of organizations, such as higher education institutions and community-based organizations, with a maximum funding amount of $499,000 per year for projects not exceeding five years. Interested parties should submit their applications through Grants.gov, with deadlines beginning January 5, 2025, and can direct inquiries to grantsinfo@nih.gov for further information.
    Development of Animal Models and Related Biological Materials for Research (R21 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a Notice of Funding Opportunity (NOFO) for the development of animal models and related biological materials for research, designated as an R21 Exploratory/Developmental Research Grant. This funding initiative aims to support innovative projects that enhance, characterize, and preserve animal models relevant to human health and diseases, with a focus on studies that encompass multiple body systems or disease categories rather than single-disease research. The total funding available is $200,000, with a project period limited to two years, and applications are due by January 7, 2028. Interested applicants can find more information and guidance by contacting NIH Grants Information at grantsinfo@nih.gov or visiting the official announcement at https://grants.nih.gov/grants/guide/pa-files/PAR-25-273.html.
    Resource-Related Research Projects for Development of Models and Related Materials for Studying Human Health and Diseases (R24 Clinical Trials Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for Resource-Related Research Projects aimed at developing models and methodologies for studying human health and diseases, specifically through the R24 grant mechanism, which does not allow clinical trials. This initiative, led by the Office of Research Infrastructure Programs (ORIP), seeks applications that focus on creating broadly applicable research models or new approach methodologies (NAMs) that address diseases impacting multiple organ systems, with a requirement that projects demonstrate relevance to two or more NIH Institutes or Centers. The NIH plans to allocate $5 million annually from fiscal years 2026 to 2029, funding at least six awards each year, with a maximum project duration of four years. Interested applicants, excluding foreign organizations, must complete federal registrations prior to submission and can direct inquiries to ORIPDCM@mail.nih.gov.
    Academic-Industrial Partnerships for Translation of Technologies for Diagnosis and Treatment (R01 - Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Cancer Institute (NCI), is offering a funding opportunity titled "Academic-Industrial Partnerships for Translation of Technologies for Diagnosis and Treatment (R01 - Clinical Trial Optional)." This initiative aims to foster interdisciplinary research teams that can translate scientific discoveries into practical tools and methods for diagnosing and treating diseases, addressing both clinical and non-clinical challenges. The program is particularly significant for enhancing cancer research and improving patient care outcomes, with a maximum funding amount of $499,000 per year available for projects lasting up to five years. Applications will be accepted starting January 5, 2025, with a closing date of January 8, 2028. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov or visit the opportunity's webpage at https://grants.nih.gov/grants/guide/pa-files/PAR-25-337.html.
    Resource-Related Research Projects for Development of Models and Related Materials for Studying Human Health and Diseases (R24 Clinical Trials Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a grant opportunity titled "Resource-Related Research Projects for Development of Models and Related Materials for Studying Human Health and Diseases (R24 Clinical Trials Not Allowed)." This funding aims to support small businesses in developing, characterizing, or improving research models related to human health and diseases, as well as creating new approach methodologies (NAMs) that enhance the accessibility and translational value of experimental research models. The initiative is crucial for advancing biomedical research and ensuring that developed resources are broadly applicable across multiple NIH Institutes or Centers. The estimated total program funding is $5 million, with approximately six awards expected. Interested applicants should prepare to submit their proposals by January 25, 2026, with the anticipated award date set for October 1, 2026. For further inquiries, contact Sige Zou, PhD, at 301-435-0749 or via email at sige.zou@nih.gov.
    Toward Translation of Nanotechnology Cancer Interventions (TTNCI; R01 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Toward Translation of Nanotechnology Cancer Interventions" (TTNCI), aimed at supporting advanced pre-clinical research in nanotechnology-based cancer diagnostics and therapeutics. This initiative encourages innovative projects that utilize nanoparticle formulations or nano-devices to address significant clinical objectives in cancer treatment, with a focus on enhancing treatment efficacy through combination therapies and immunotherapy. Funding is available up to $475,000 annually for a maximum of four years, with applications accepted from eligible institutions including higher education entities, nonprofits, and government organizations. Interested applicants should refer to the detailed application process outlined on Grants.gov and the NIH ASSIST system, with key deadlines spanning from April 2025 to November 2027. For further inquiries, contact NIH Grants Information at grantsinfo@nih.gov.
    Intramural - Extramural Collaboration for Advanced 3-D Tissue Models for Drug Screening (Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Intramural - Extramural Collaboration for Advanced 3-D Tissue Models for Drug Screening," aimed at developing and validating advanced 3-D tissue models for drug efficacy testing. This initiative seeks to create non-animal models that accurately mimic the physiological properties of human tissues, thereby enhancing the predictive accuracy of drug screening processes. With an estimated total program funding of $1,600,000 and the expectation of awarding two grants, interested applicants are encouraged to utilize the resources available at the NCATS 3-D Bioprinting laboratory. The application process is open to various eligible entities, excluding non-domestic applicants, with a submission deadline anticipated by June 16, 2026. For further inquiries, potential applicants can contact Dobrila D. Rudnicki, Ph.D., at dobrila.rudnicki@nih.gov or by phone at 240-535-6621.
    Animal and Biological Material Resource Centers (P40 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity for the establishment of Animal and Biological Material Resource Centers under the Notice of Funding Opportunity (NOFO) RFA-OD-25-011. This initiative aims to support the creation, preservation, and distribution of high-quality laboratory animals and biological materials, while also integrating new approach methodologies (NAMs) that complement traditional animal-based research. The program is crucial for enhancing research infrastructure and ensuring the availability of resources that facilitate scientific rigor and reproducibility in biomedical research. A total funding amount of $1.3 million is anticipated to support at least two awards annually from FY 2023-2025, with applications due by January 9, 2029. Interested applicants can reach out to the Office of Research Infrastructure Programs at ORIPDCM@mail.nih.gov for further information.
    Metastasis Research Network (U54 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the Metastasis Research Network (U54 Clinical Trial Not Allowed), aimed at advancing research on cancer metastasis through the establishment of specialized centers. Applicants are required to propose a cohesive scientific theme supported by two or three interdisciplinary research projects that utilize integrative system-level approaches to understand the complexities of metastasis, including factors such as early dissemination and cellular responses to therapies. This initiative is crucial for enhancing our understanding of metastasis as a systemic issue across various cancer types, including rare and pediatric cancers. The total estimated funding for this program is $6.8 million, with individual awards capped at $1.7 million, and the application deadline is expected to close on May 15, 2026. For further inquiries, interested parties can contact Joanna M. Watson, Ph.D., at 240-276-6206 or via email at watsonjo@mail.nih.gov.
    Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Development and Validation of Model Systems to Facilitate Neurotherapeutic Discovery (R61/R33 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Innovation Grants to Nurture Initial Translational Efforts (IGNITE)" aimed at developing and validating model systems for neurotherapeutic discovery. This initiative encourages proposals for animal models or ex vivo systems that accurately replicate the characteristics of specific neurological or neuromuscular disorders, with the goal of enhancing the translational relevance of these models to improve drug development processes. The program utilizes a phased award mechanism (R61/R33) and requires collaboration with clinical experts, along with a Plan for Enhancing Diverse Perspectives (PEDP) to promote inclusivity in research. The total funding available is $750,000 over three years, with a maximum of $499,000 in direct costs per year. Key submission dates begin with the earliest application due date of January 18, 2025. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.